The third part of this three-part series on executing an effective remediation program starts by looking at the importance of communication to the overall project. It also looks at, and answers, that age old question of ‘how long does a remediation project take to complete?’.
Executing a successful remediation program: part 3 of 3
Learn how NSF's Pharma Biotech experts help clients with remediation strategy, including FDA Warning Letters
Promoted Content
You may also like
Analysis
Inspection readiness should be part of normal operations
Read moreFor routine surveillance inspections, readiness cannot depend on receiving advance notice. Inspection readiness should be embedded in everyday operations, while recognising that preparation may need to become more intensive ahead of a known regulatory milestone
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
Analysis
Inspection readiness should be part of normal operations
For routine surveillance inspections, readiness cannot depend on receiving advance notice. Inspection readiness should be embedded in everyday operations, while recognising that preparation may need to become more intensive ahead of a known regulatory milestone
Regulatory
EU combination products: MDR, article 117 and drug-device approval risks
Bringing a drug-device combination product to market in Europe requires more than a strong pharmaceutical dossier and a functional delivery device. Companies must align two different development models, satisfy EU MDR expectations, manage notified-body involvement, and demonstrate that the drug and device work safely as one integrated product
Regulatory
Is your combination product really submission-ready?
A pharmaceutical team may consider a combination product nearly ready because the clinical, stability, quality, and drug data are in place. At the same time, the device team may still be completing design verification, usability studies, risk-management activities, or notified-body preparation
Analysis
Quality culture becomes visible during an inspection
Quality culture can sound intangible, but investigators encounter evidence of it throughout an inspection. Is your quality system ready for regulatory scrutiny? Former FDA investigator Dr. Julia Marré shares practical guidance on quality culture, site preparation and effective Form FDA 483 responses
Manufacturing
Why CAPA keeps failing and what strong organisations do differently
This white paper examines why CAPA systems often close records without preventing recurrence, tracing breakdowns to investigation quality, risk reasoning, and organisational behaviour rather than procedural gaps. It outlines what differentiates compliant CAPA programmes from those that consistently reduce repeat findings and inspection risk